United Pharmaceuticals
13
2
3
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
23%
3 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)
Role: lead
Evaluation of Tolerance, Efficacy and Safety of an Hydrolyzed Formula in Infants With IgE/Non-IgE Mediated CMA.
Role: lead
Evolution of Functional Gastrointestinal Disorders in Infants Fed With a New Infant Formula
Role: lead
Evaluation of an Adapted Formula on Atopic Dermatitis.
Role: lead
Evaluation of the Efficacy of a New Specific Infant Formula in Case of Functional Constipation
Role: lead
Evaluation of the Hypoallergenicity of a New Formula Based on Hydrolyzed Rice Proteins
Role: lead
Evaluation of the Hypoallergenicity of an Extensively Hydrolyzed Formula
Role: lead
SWAN: Study on the Tolerance and Efficacy of a New Anti-regurgitation Formula (PC-2016-01)
Role: lead
Study on the Tolerance and Efficacy of a New Anti Regurgitation Formula
Role: lead
Efficacy of a New Thickened Extensively Hydrolyzed Formula
Role: lead
A Double-blind Randomized Controlled Trial of a Thickened Amino-acid-based Formula in Children Allergic to Cow's Milk and to Protein Hydrolysates
Role: lead
Cow Milk Allergy: Evaluation of the Efficacy of a New Thickened Extensively Hydrolyzed Formula in Infants With Confirmed Cow Milk Allergy
Role: lead
Evaluation of the Efficacy of a New Formula in Infants With Cow's Milk Protein Allergy
Role: lead
All 13 trials loaded